Previous 10 | Next 10 |
AVEO Oncology (NASDAQ:AVEO) says it will begin manufacturing a clinical supply of ficlatuzumab, its candidate for head and neck squamous cell carcinoma, in Q2 2022. The company is also eying the start of a potential registrational trial in the human papillomavirus negative populati...
AVEO Pharmaceuticals (NASDAQ:AVEO): Q3 GAAP EPS of -$0.30 beats by $0.06. Revenue of $15.17M (+321.4% Y/Y) beats by $1.37M. Press Release In 2021, AVEO expects commercial spend will be approximately $40 million, research and development expense will be approximately $30 million and general an...
– Total Q3 2021 Revenue of $15.2 Million Includes FOTIVDA ® (tivozanib) U.S. Net Product Revenue of $14.3 Million – – Enrollment Open for Pivotal Phase 3 TiNivo-2 Clinical Trial of FOTIVDA ® (tivozanib) in Combination with OPDIVO ® (ni...
AVEO Pharmaceuticals (NASDAQ:AVEO) is scheduled to announce Q3 earnings results on Monday, November 8th, after market close. The consensus EPS Estimate is -$0.35 and the consensus Revenue Estimate is $13.8M (+283.3% Y/Y). The company posted second-quarter revenue and profit that beat Wal Stre...
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it will report third quarter 2021 financial results on Monday, November 8, 2021. AVEO’s management team will host a conference call and audio webcast at 4:30 p.m. ET...
AVEO Pharmaceuticals believes that they are off to a strong start. It looks as if the first full quarter of FOTIVDA sales show there was some demand at launch. I am remaining cautiously optimistic about FOTIVDA’s launch and expect the Street to be skeptical about Aveo's commerc...
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to ficlatuzumab for the treatment of patients with relapsed or recurrent head and neck ...
AVEO Oncology (Nasdaq: AVEO) today announced that members of its senior management team will participate in two upcoming virtual investor conferences: H.C. Wainwright 23 rd Annual Global Investment Conference Date: Monday, September 13 Time: 7:00 a.m. Eastern Time ...
AVEO Pharmaceuticals, Inc. (AVEO) Q2 2021 Earnings Conference Call August 05, 2021 04:30 PM ET Company Participants Erick Lucera - Chief Financial Officer Michael Bailey - Chief Executive Officer Mike Ferraresso - Chief Commercial Officer Michael Needle - Chief Medical Officer Conference Call...
AVEO Pharmaceuticals (NASDAQ:AVEO): Q2 GAAP EPS of -$0.40 beats by $0.10. Revenue of $7.6M (+913.3% Y/Y) beats by $0.64M. AVEO believes its $102.9M in cash, cash equivalents and marketable securities as of June 30, 2021, along with expected net product revenues from the commercial launch of F...
News, Short Squeeze, Breakout and More Instantly...
AVEO Pharmaceuticals Inc. Company Name:
AVEO Stock Symbol:
NASDAQ Market:
SEOUL, South Korea, Jan. 19, 2023 (GLOBE NEWSWIRE) -- LG Chem, Ltd. (“LG Chem”) (KOSPI: 051910) today announced that it has completed its previously announced acquisition of AVEO Oncology (“AVEO”), a commercial stage, oncology-focused biopharmaceutical company committe...
BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, announced that at a special meeting of stockholders ...
BOSTON, Jan. 03, 2023 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, reminds all AVEO stockholders to vote before AVEO...